Agomelatine and its therapeutic potential in the depressed patient

References

• ArmstrongSMMcNultyOMGuardiola-LemaitreB1993Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS)Pharmacol Biochem Behav464598255922
   PubMed Web of Science ®Google Scholar
• AudinotVMaillietFLahayeBC2003New selective ligands of human cloned melatonin MT1 and MT2 receptorsNaunyn Schmiede-bergs Arch Pharmacol655361
   Google Scholar
• BanasrMSoumierAHeryM2006Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesisBiol Psychiatry5910879616499883
   PubMed Web of Science ®Google Scholar
• BardenNShinkELabbeM2005Antidepressant action of agomelatine (S 20098) in a transgenic mouse modelProg Neuropsychopharmacol Biol Psychiatry299081616005135
   PubMed Web of Science ®Google Scholar
• Bertaina-AngladeVDrieu la RochelleCBoyerPA2006Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness modelBehav Pharmacol177031317110796
   PubMed Web of Science ®Google Scholar
• BogaardsJJHissinkEMBriggsM2000Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modelingEur J Pharm Sci121172411102739
   PubMed Web of Science ®Google Scholar
• BoivinDB2000Influence of sleep-wake and circadian rhythm disturbances in psychiatric disordersJ Psychiatry Neurosci254465811109296
   PubMed Web of Science ®Google Scholar
• BourinMMocaerEPorsoltR2004Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptorsJ Psychiatry Neurosci291263315069466
   PubMed Web of Science ®Google Scholar
• ClaytonAHPradkoJFCroftHA2002Prevalence of sexual dysfunction among newer antidepressantsJ Clin Psychiatry633576612000211
   PubMed Web of Science ®Google Scholar
• den BoerJABoskerFJMeestersY2006Clinical efficacy of agomelatine in depression: the evidenceInt Clin Psychopharmacol21Suppl 1S21416436936
   PubMed Web of Science ®Google Scholar
• DijkDJCajochenC1997Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEGJ Biol Rhythms12627359406038
   PubMed Web of Science ®Google Scholar
• DubocovichML2006Drug evaluation: Agomelatine targets a range of major depressive disorder symptomsCurr Opin Investig Drugs767080
   PubMed Web of Science ®Google Scholar
• DumanRSMonteggiaLM2006A neurotrophic model for stress-related mood disordersBiol Psychiatry5911162716631126
   PubMed Web of Science ®Google Scholar
• DuxonMSFlanaganTPReavleyAC1997Evidence for expression of the 5-hydroxytrypamine2B receptor profile in the rat central nervous systemNeuroscience7632399015317
   PubMed Web of Science ®Google Scholar
• FuchsESimonMSchmeltingB2006Pharmacology of a new antide-pressant: benefit of the implication of the melatonergic systemInt Clin Psychopharmacol21Suppl 1S172016436935
   PubMed Web of Science ®Google Scholar
• GuelfiJDCalabreseJR2005Efficacy and safety of the new antidepressant agomelatine in combination with mood stabilizer in bipolar I patients with a major depressive episodeBipolar Disord7Suppl 263
   Google Scholar
• GuilleminaultC2005Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorderEur Neuropsychopharmacol15Suppl 3S419
   Google Scholar
• HamiltonM1959The assessment of anxiety states by ratingBr J Med Psychol3250513638508
   PubMed Web of Science ®Google Scholar
• HamiltonM1960A rating scale for depressionJ Neurol Neurosurg Psychiatry23566214399272
   PubMed Web of Science ®Google Scholar
• HanounNMocaerEBoyerPA2004Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brainNeuropharmacology475152615380370
   PubMed Web of Science ®Google Scholar
• KennedySH2005Sexual function in remitted depressed patients following agomelatine and venlafaxine XR treatmentEur Neuropsychpharmacol15Suppl 3S440
   Google Scholar
• KennedySH2006Favourable sexual profile of agomelatine in depressed patientsEur Neuropsychopharmacol16Suppl 4S319
   Google Scholar
• KennedySHDickensSEEisfeldBS1999Sexual dysfunction before antidepressant therapy in major depressionJ Affect Disord56201810701478
   PubMed Web of Science ®Google Scholar
• KennedySHEisfeldBSDickensSE2000Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxineJ Clin Psychiatry612768110830148
   PubMed Web of Science ®Google Scholar
• KennedySHEisfeldBSMeyerJH2001Antidepressants in clinical practice: limitations of assessment methods and drug responseHum Psychopharmacol1610511412404605
   PubMed Web of Science ®Google Scholar
• KennedySHEmsleyR2006Placebo-controlled trial of agomelatine in the treatment of major depressive disorderEur Neuropsychopharmacol169310016249073
   PubMed Web of Science ®Google Scholar
• KennedySHFultonKABagbyRM2006Sexual function during bupropion or paroxetine treatment of major depressive disorderCan J Psychiatry512344216629348
   PubMed Web of Science ®Google Scholar
• KennedySHGuilleminaultC2006Antidepressant efficacy of agomelatine 25–50 mg versus venlafaxine 75–150 mg: two randomized, double-blind studiesEur Neuropsychopharmacol16Suppl 4S31920
   Google Scholar
• KrauchiKWirz-JusticeA2001Circadian clues to sleep onset mechanismsNeuropsychopharmacology255 SupplS92611682282
   PubMed Web of Science ®Google Scholar
• LeproultRVan OnderbergenAL’hermite-BaleriauxM2005Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older menClin Endocrinol (Oxf)6329830416117817
   PubMed Web of Science ®Google Scholar
• LooHHaleAD’haenenH2002Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range studyInt Clin Psychopharmacol172394712177586
   PubMed Web of Science ®Google Scholar
• LopesMSQuera-SalvaMAGuilleminaultC2005Cyclic Alternating Pattern in the NREM sleep of patients within major depression disorder: Baseline results and change over time with a new antidepressant: AgomelatineSleep Med6Suppl 287815680304
   PubMed Web of Science ®Google Scholar
• Lopez-IborJGuelfiJDPletanY1996Milnacipran and selective serotonin reuptake inhibitors in major depressionInt Clin Psychopharmacol11Suppl 44168923126
   PubMed Web of Science ®Google Scholar
• MalbergJESchechterLE2005Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugsCurr Pharm Des111455515638755
   PubMed Web of Science ®Google Scholar
• MartinetLGuardiola-LemaitreBMocaerE1996Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependentPharmacol Biochem Behav5471388853194
   PubMed Web of Science ®Google Scholar
• McGahueyCAGelenbergAJLaukesCA2000The Arizona Sexual Experience Scale (ASEX): reliability and validityJ Sex Marital Ther26254010693114
   PubMed Web of Science ®Google Scholar
• MillanMJ2004The role of monoamines in the actions of established and “novel” antidepressant agents: a critical reviewEur J Pharmacol5003718415464046
   PubMed Web of Science ®Google Scholar
• MillanMJGobertALejeuneF2003The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathwaysJ Pharmacol Exp Ther3069546412750432
   PubMed Web of Science ®Google Scholar
• MillanMJBroccoMGobertA2005Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockadePsychopharmacology (Berl)1774485815289999
   PubMed Web of Science ®Google Scholar
• MontgomerySAAsbergM1979A new depression scale designed to be sensitive to changeBr J Psychiatry1343829444788
   PubMed Web of Science ®Google Scholar
• MontgomerySABaldwinDSRileyA2002Antidepressant medications: a review of the evidence for drug-induced sexual dysfunctionJ Affect Disord691194012103459
   PubMed Web of Science ®Google Scholar
• MontgomerySAKennedySHBurrowsGD2004Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation studyInt Clin Psychopharmacol192718015289700
   PubMed Web of Science ®Google Scholar
• PappMGrucaPBoyerPA2003Effect of agomelatine in the chronic mild stress model of depression in the ratNeuropsychopharmacology2869470312655314
   PubMed Web of Science ®Google Scholar
• PappMLitwaEGrucaP2006Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxietyBehav Pharmacol1791816377959
   PubMed Web of Science ®Google Scholar
• ParrottACHindmarchI1978Factor analysis of a sleep evaluation questionnairePsychol Med8325926096
   PubMed Web of Science ®Google Scholar
• PineyroGBlierP1999Autoregulation of serotonin neurons: role in antidepressant drug actionPharmacol Rev515339110471417
   PubMed Web of Science ®Google Scholar
• Quera-SalvaMAVanierBChapototF2005Effects of agomelatine on the sleep EEG in patients with major depressive disorderJ Eur Coll Neuropsychopharmacol15Suppl 3S435
   PubMed Web of Science ®Google Scholar
• RadhakishunFSvan den BosJvan der HeijdenBC2000Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimensJ Clin Psychopharmacol20531711001237
   PubMed Web of Science ®Google Scholar
• RedmanJRGuardiola-LemaitreBBrownM1995Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythmsPsychopharmacology (Berl)118385907568624
   PubMed Web of Science ®Google Scholar
• RosenbaumJFFavaMHoogSL1998Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trialBiol Psychiatry4477879646889
   PubMed Web of Science ®Google Scholar
• RouillonF2006Efficacy and tolerance profile of agomelatine and practical use in depressed patientsInt Clin Psychopharmacol21Suppl 1S31516436938
   PubMed Web of Science ®Google Scholar
• SimonMSchmeltingBMolzërE2004Agomelatine restores sleep EEG activity in chronically stressed tree shrews Program no 354.10Abstract viewer Itinerary PlannerSociety for NeurosciencesSan Diego
   Google Scholar
• SmithDDempsterCGlanvilleJ2002Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysisBr J Psychiatry18039640411983635
   PubMed Web of Science ®Google Scholar
• ThaseMEEntsuahARRudolphRL2001Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitorsBr J Psychiatry1782344111230034
   PubMed Web of Science ®Google Scholar
• TrivediMHRushAJWisniewskiSR2006Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry163284016390886
   PubMed Web of Science ®Google Scholar
• TumaJStrubbeJHMocaerE2005Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCNEur Neuropsychopharmacol155455516139172
   PubMed Web of Science ®Google Scholar
• VacherRLabbeMBardenN2002Antidepressant action of S-20098 (agomelatine) in a transgenic mouse modelInt J Neuropsychopharmacol5Suppl 1S64
   Google Scholar
• van RossumEFBinderEBMajerM2006Polymorphisms of the glucocorticoid receptor gene and major depressionBiol Psychiatry59681816580345
   PubMed Web of Science ®Google Scholar
• VanderkooyJDKennedySHBagbyRM2002Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxineCan J Psychiatry471748011926080
   PubMed Web of Science ®Google Scholar
• WilsonSArgyropoulosS2005Antidepressants and sleep: a qualitative review of the literatureDrugs659274715892588
   PubMed Web of Science ®Google Scholar